Login to Your Account



Offer Raised to $62 Per Share

BMS Goes Hostile, Takes Higher Offer to ImClone Shareholders

By Jennifer Boggs


Wednesday, September 24, 2008
Bristol-Myers Squibb Co. hasn't given up trying to acquire Erbitux partner ImClone Systems Inc. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription